Strides Pharma Science Secures USFDA Approval for Celecoxib Capsules, Expands U.S. Portfolio

Strides Pharma Science Ltd has received approval from the U.S. Food and Drug Administration (USFDA) for its Celecoxib Capsules, marking a significant addition to the company’s growing U.S. generics portfolio. The approved product is a generic version of Celecoxib, a widely prescribed nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with conditions such as arthritis, acute pain, and menstrual discomfort.

 

The manufacturing for the newly approved Celecoxib Capsules will take place at Strides Pharma’s advanced facility in Puducherry, India, further leveraging the company’s robust infrastructure and compliance track record. This USFDA nod not only strengthens Strides Pharma’s presence in the competitive U.S. market but also reinforces its commitment to providing high-quality, affordable medications to patients globally.

 

Management highlighted that the approval is in line with Strides Pharma’s strategy to expand its product offerings in regulated markets, particularly in the U.S., where demand for cost-effective generic medicines continues to rise. The company’s expanding pipeline and consistent regulatory successes position it well for future growth and enhanced market share.

 

Source: Business Upturn